FORMA Therapeutics Receives FDA Orphan Drug Designation For FT-4202 For The Treatment Of Sickle Cell Disease

WATERTOWN, Mass.  – April 15, 2020 – FORMA Therapeutics, Inc. (FORMA), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for FORMA’s lead investigational agent, FT-4202, currently in clinical development as a potentially disease-modifying …

Continue reading